Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors

Inclusion Criteria: * Subject is able to understand the study procedures, the risks involved and willing to provide written informed consent before the first study related activity. * Subject meets the diagnosis of gout as per the American Rheumatism Association Criteria for the Classification of Acute Arthritis of Primary Gout. * Subject has an sUA level ≥ 6.5 mg/dL at the Screening and Day -7 Visits. * Subject must be able to take gout flare prophylaxis with colchicine or NSAID (including Cox-2 selective NSAID) ± PPI. * Subject has a history (either by medical record or subject interview) of intolerance or a contraindication to either allopurinol or febuxostat. * Body mass index (BMI) \< 45 kg/m2 Exclusion Criteria: * Subject who is taking any other approved urate-lowering medication that is indicated for the treatment of gout at the Screening Visit. * Subject with a documented history or suspicion of kidney stones. * Subject who is pregnant or breastfeeding. * Subject who consumes more than 14 drinks of alcohol per week (eg, 1 drink = 5 oz \[150 mL\] of wine, 12 oz \[360 mL\] of beer, or 1.5 oz \[45 mL\] of hard liquor). * Subject with a history or suspicion of drug abuse within the past 5 years. * Subject that requires or may require systemic immunosuppressive or immunomodulatory treatment. * Subject with a known or suspected human immunodeficiency virus (HIV) infection. * Subject with a positive test for active hepatitis B or hepatitis C infection. * Subject with a history of malignancy within the previous 5 years with the exception of non-melanoma skin cancer that has been treated with no evidence of recurrence, treated cervical dysplasia or treated in situ Grade 1 cervical cancer. * Subject within the last 12 months with: unstable angina, New York Heart Association class III or IV heart failure, myocardial infarction, stroke, or deep venous thrombosis; or subjects currently receiving anticoagulants. * Subject with uncontrolled hypertension. * Subject with an estimated creatinine clearance \< 30 mL/min. * Subject with active peptic ulcer disease requiring treatment. * Subject with active liver disease, or hepatic dysfunction. * Subject receiving chronic treatment with more than 325 mg salicylates per day. * Subject taking valpromide, progabide, or valproic acid. * Subject who has received an investigational therapy within 8 weeks or 5 half-lives (whichever is longer) prior to the Screening Visit. * Subject with any other medical or psychological condition, which in the opinion of the Investigator and/or Medical Monitor, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements, or to complete the study.